BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34743406)

  • 1. USP22-mediated deubiquitination of PTEN inhibits pancreatic cancer progression by inducing p21 expression.
    Ren D; Sun Y; Li D; Wu H; Jin X
    Mol Oncol; 2022 Mar; 16(5):1200-1217. PubMed ID: 34743406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
    Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
    Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
    Wan W; Hou Y; Wang K; Cheng Y; Pu X; Ye X
    Cell Death Dis; 2019 Mar; 10(3):248. PubMed ID: 30867411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells.
    Han CT; Schoene NW; Lei KY
    Am J Physiol Cell Physiol; 2009 Nov; 297(5):C1188-99. PubMed ID: 19657064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.
    Zheng T; Meng X; Wang J; Chen X; Yin D; Liang Y; Song X; Pan S; Jiang H; Liu L
    J Cell Biochem; 2010 Sep; 111(1):218-28. PubMed ID: 20506484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectodomain-specific E-cadherin antibody suppresses skin SCC growth and reduces tumor grade: a multitargeted therapy modulating RTKs and the PTEN-p53-MDM2 axis.
    Brouxhon SM; Kyrkanides S; Raja V; Silberfeld A; Teng X; Trochesset D; Cohen J; Ma L
    Mol Cancer Ther; 2014 Jul; 13(7):1791-802. PubMed ID: 24748654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
    Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
    J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research on miR-126 in glioma targeted regulation of PTEN/PI3K/Akt and MDM2-p53 pathways.
    Chen SR; Cai WP; Dai XJ; Guo AS; Chen HP; Lin GS; Lin RS
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3461-3470. PubMed ID: 31081101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response.
    Lim KH; Park JJ; Gu BH; Kim JO; Park SG; Baek KH
    Sci Rep; 2015 Aug; 5():12793. PubMed ID: 26238070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.
    Mayo LD; Seo YR; Jackson MW; Smith ML; Rivera Guzman J; Korgaonkar CK; Donner DB
    J Biol Chem; 2005 Jul; 280(28):25953-9. PubMed ID: 15843377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K/AKT signaling.
    Shen WM; Yin JN; Xu RJ; Xu DF; Zheng SY
    Kaohsiung J Med Sci; 2019 Jul; 35(7):401-407. PubMed ID: 31001918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
    Giono LE; Manfredi JJ
    Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein phosphatase 5 and the tumor suppressor p53 down-regulate each other's activities in mice.
    Wang J; Shen T; Zhu W; Dou L; Gu H; Zhang L; Yang Z; Chen H; Zhou Q; Sánchez ER; Field LJ; Mayo LD; Xie Z; Xiao D; Lin X; Shou W; Yong W
    J Biol Chem; 2018 Nov; 293(47):18218-18229. PubMed ID: 30262665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
    Nakanishi A; Kitagishi Y; Ogura Y; Matsuda S
    Int J Oncol; 2014 Jun; 44(6):1813-9. PubMed ID: 24718924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN regulates Mdm2 expression through the P1 promoter.
    Chang CJ; Freeman DJ; Wu H
    J Biol Chem; 2004 Jul; 279(28):29841-8. PubMed ID: 15090541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. USP49-Mediated Histone H2B Deubiquitination Regulates HCT116 Cell Proliferation through MDM2-p53 Axis.
    Shi L; Shen X; Shen Y
    Mol Cell Biol; 2022 Mar; 42(3):e0043421. PubMed ID: 35072515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.
    Huang X; Zhang Y; Tang Y; Butler N; Kim J; Guessous F; Schiff D; Mandell J; Abounader R
    Neoplasia; 2013 Aug; 15(8):952-65. PubMed ID: 23908595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of expression of the p21
    Mantsou A; Koutsogiannouli E; Haitoglou C; Papavassiliou AG; Papanikolaou NA
    Biochem Cell Biol; 2016 Dec; 94(6):560-568. PubMed ID: 27792410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.